ReviewJournal of clinical medicine2019
Therapy of Patients with Neuroendocrine Neoplasia-Evidence-Based Approaches and New Horizons.
Review in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 10 citations in OpenAlex.
- Immunogenic cell death as a mechanism of synergy between sunitinib andCell death discovery · 2026Article
- Survival Outcomes in Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis of Progression-Related Endpoints.Cancers · 2026Review
- Advances in the management of neuroendocrine tumours: Evidence from a systematic review.Biomedical reports · 2026Article
- In-Vivo Somatostatin-Receptor Expression in Small Cell Lung Cancer as a Prognostic Image Biomarker and Therapeutic Target.Cancers · 2023Article
- A Lymph Node Ratio Model for Prognosis of Patients with Pancreatic Neuroendocrine Tumors.Biomedicines · 2023Article
- Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives.Japanese journal of clinical oncology · 2021Review
- Article
- Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors.JAMA network open · 2021Article
- Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy ofCancers · 2021Article
- Somatostatinoma: Beyond neurofibromatosis type 1 (Review).Experimental and therapeutic medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine tumors (NETs) show low but increasing incidence and originate in multiple organs, including the pancreas, midgut, caecum, rectum, appendix, colon, and lungs. Due to their stunning genetic, histological, and clinical variability, diagnosis and treatment of NETs are challenging. In addition, low incidence and high variability hamper the implementation of high evidence trials. Therefore, guidelines do not cover the complexity of NETs and, frequently, treatment decisions are taken by interdisciplinary tumor conferences at comprehensive cancer centers. Treatment aims are (i) control of tumor growth, (ii) symptom control, as well as (iii) the improvement of progression-free survival (PFS) and overall survival (OS). Here, we discuss high evidence trials facilitating the achievement of these treatment aims. The majority of the evidence exists for treatment with somatostatin analogue, everolimus, peptide receptor radionuclide therapy (PRRT) with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.